CYB5R1 Antibody

CYB5R1 Antibody Characteristics

CYB5R1 antibodies are polyclonal or monoclonal reagents validated for use in techniques such as Western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF/ICC), immunoprecipitation (IP), and ELISA. Key features include:

Validation and Applications

CYB5R1 antibodies have been rigorously tested across diverse experimental settings:

Key Validation Data

• Western Blot: Detects CYB5R1 in human placenta, brain tissue, and cancer cell lines (e.g., PC-3) .

• IHC: Strong staining in breast cancer tissues with antigen retrieval (TE buffer pH 9.0 recommended) .

• Functional Studies: Used to link CYB5R1 to epithelial-mesenchymal transition (EMT) in colorectal cancer (CRC) and drug resistance in gastric cancer (GC) .

Research Findings

• Cancer Prognosis: High CYB5R1 expression correlates with poor survival in CRC (HR = 1.57 for OS, p = 4.1e−05) and GC (HR = 1.34 for OS, p = 0.00078) .

• Drug Resistance: CYB5R1 knockdown sensitizes GC cells to 5-FU and oxaliplatin, reducing IC50 values by up to 50% .

• Stemness and EMT: CYB5R1 promotes spheroid formation (a stemness marker) and enhances migratory/invasive capacities in CRC and GC .

Clinical and Molecular Correlations

CYB5R1’s role in disease is underscored by its associations with:

Protocols and Usage Guidelines

• Storage: Stable at -20°C in PBS with 0.02% sodium azide and 50% glycerol .

• Antigen Retrieval: For IHC, use TE buffer (pH 9.0) or citrate buffer (pH 6.0) .

• Controls: Include CYB5R1-high cell lines (e.g., MKN45, HGC27) and normal tissues (e.g., placenta) for validation .

Future Directions

Current research explores CYB5R1’s interaction with NFS1 (a Fe-S cluster biogenesis enzyme) and its role in ferroptosis resistance . Targeting the CYB5R1-NFS1 axis may improve chemosensitivity in GC and CRC .